Literature DB >> 33704358

Patient Perceptions of SARS-CoV-2 Exposure Risk and Association With Continuity of Ophthalmic Care.

Aaron Lindeke-Myers1, Peter Yu Cheng Zhao2, Benjamin I Meyer1, Elaine A Liu3, David A Levine4, Olivia M Bennett3, Sunjong Ji3, Paula Anne Newman-Casey2, Rajesh C Rao2,5,6,7,8,9, Nieraj Jain4.   

Abstract

Importance: Patient perceptions regarding the risks of obtaining in-person ophthalmic care during the coronavirus disease 2019 (COVID-19) pandemic may affect adherence to recommended treatment plans and influence visual outcomes. A deeper understanding of patient perspectives will inform strategies to optimize adherence with vision-preserving therapies. Objective: To evaluate perceptions of COVID-19 exposure risk and their association with appointment attendance among patients at high risk of both reversible and irreversible vision loss from lapses in care. Design, Setting, and Participants: This survey study included a nonvalidated telephone survey designed in April and May of 2020 and a retrospective medical record review conducted in parallel with survey administration from May 22 to August 18, 2020. Participants were recruited from 2 tertiary eye care centers (Emory Eye Center in Atlanta, Georgia, and W.K. Kellogg Eye Center in Ann Arbor, Michigan). The study included a random sample of patients with diagnoses of exudative age-related macular degeneration (AMD) or diabetic retinopathy (DR) who received an intravitreal injection between January 6 and March 13, 2020, and were scheduled for a second injection between March 13 and May 6, 2020. Main Outcomes and Measures: Association between perceptions regarding COVID-19 risks and loss to follow-up.
Results: Of 1004 eligible patients, 423 (42%) were successfully contacted, and 348 (82%) agreed to participate (participants' mean [SD] age, 75 [12] years; 195 women [56%]; 287 White [82%] patients). Respondents had a mean (SD) of 2.7 (1.1) comorbidities associated with severe COVID-19, and 77 (22%) knew someone with COVID-19. Of all respondents, 163 (47%) were very concerned or moderately concerned about vision loss from missed treatments during the pandemic. Although 208 (60%) believed the COVID-19 virus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), exposure at the eye clinic was extremely unlikely or unlikely, 49 (14%) believed it was extremely likely or likely. Seventy-eight participants (22%) were lost to follow-up. Concern regarding COVID-19 exposure during clinic visits (odds ratio [OR], 3.9; 95% CI, 1.8-8.4) and diagnosis of DR (vs AMD) (OR, 8.130; 95% CI, 3.367-20.408) were associated with an increase in likelihood of loss to follow-up. Conclusions and Relevance: Among patients at high risk for vision loss from lapses in care, many expressed concerns regarding the effect of the pandemic on their ability to receive timely care. Survey results suggest that fear of SARS-CoV-2 exposure was associated with a roughly 4-fold increase in the odds of patient loss to follow-up. These results support the potential importance of clearly conveying infection-control measures.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 33704358      PMCID: PMC7953331          DOI: 10.1001/jamaophthalmol.2021.0114

Source DB:  PubMed          Journal:  JAMA Ophthalmol        ISSN: 2168-6165            Impact factor:   7.389


  19 in total

1.  Risk and Impact of Severe Acute Respiratory Syndrome Coronavirus 2 Infection on Corneal Transplantation: A Case-Control Study.

Authors:  Harry Levine; Paula A Sepulveda-Beltran; Diego S Altamirano; Alfonso L Sabater; Sander R Dubovy; Harry W Flynn; Guillermo Amescua
Journal:  Cornea       Date:  2022-02-01       Impact factor: 2.651

Review 2.  Changes to ophthalmic clinical care during the coronavirus disease 2019 pandemic.

Authors:  Miel Sundararajan; Julie M Schallhorn; Thuy Doan; Gerami D Seitzman
Journal:  Curr Opin Ophthalmol       Date:  2021-11-01       Impact factor: 3.761

Review 3.  A Systematic Literature Review and Bibliometric Analysis of Ophthalmology and COVID-19 Research.

Authors:  Ali Forouhari; Vahid Mansouri; Sare Safi; Hamid Ahmadieh; Amir Ghaffari Jolfayi
Journal:  J Ophthalmol       Date:  2022-05-24       Impact factor: 1.974

4.  Opportunities of Digital Infrastructures for Disease Management-Exemplified on COVID-19-Related Change in Diagnosis Counts for Diabetes-Related Eye Diseases.

Authors:  Franziska Bathelt; Ines Reinecke; Yuan Peng; Elisa Henke; Jens Weidner; Martin Bartos; Robert Gött; Dagmar Waltemath; Katrin Engelmann; Peter Eh Schwarz; Martin Sedlmayr
Journal:  Nutrients       Date:  2022-05-11       Impact factor: 6.706

5.  Teleophthalmology and Inequities in Diabetic Eye Disease at Safety Net Hospitals.

Authors:  Molly J E Snider; Daniel Lee; Bryce Chiang; Sunil Gupta; Yousuf Khalifa; April Y Maa
Journal:  Telemed J E Health       Date:  2021-12-31       Impact factor: 5.033

6.  Trends in Self-reported Forgone Medical Care Among Medicare Beneficiaries During the COVID-19 Pandemic.

Authors:  Sungchul Park; Jim P Stimpson
Journal:  JAMA Health Forum       Date:  2021-12-30

7.  Impact of COVID-19 pandemic on ophthalmic presentations to an Australian outer metropolitan and rural emergency department: a retrospective comparative study.

Authors:  King Fai Calvin Leung; Mojtaba Golzan; Chaminda Egodage; Simon Rodda; Richard Cracknell; Peter Macken; Shweta Kaushik
Journal:  BMC Ophthalmol       Date:  2022-01-28       Impact factor: 2.209

8.  Eye Care During the COVID-19 Pandemic: A Report on Patients' Perceptions and Experiences, an Asian Perspective.

Authors:  Rebecca Low; Jia Min Lee; Ser Sei Lai; Andrés Rousselot; Manisha Agarwal; Rupesh Agrawal
Journal:  Ophthalmol Ther       Date:  2021-12-22

Review 9.  The Impact of COVID-19 on Diabetic Retinopathy Monitoring and Treatment.

Authors:  Ishrat Ahmed; T Y Alvin Liu
Journal:  Curr Diab Rep       Date:  2021-09-08       Impact factor: 4.810

10.  The Impact of Non-Ophthalmic Factors on Intravitreal Injections During the COVID-19 Lockdown.

Authors:  Sahar Ashrafzadeh; Bradley S Gundlach; Irena Tsui
Journal:  Clin Ophthalmol       Date:  2021-08-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.